Application/Control Number: 09/833,637

Art Unit: 1653

Proposed Examiner's Amendments to the claims:

Cancel claim 24.

Claims 23, 26, 27, 29, 32 and 35-38 have been amended as follows:

Claim 23 (Currently amended) A pharmaceutical composition for treating a gastrointestinal disease caused by *Helicobacter pylori* in mammals, comprising the inhibitor composition according to Claim 22 and a pharmaceutically acceptable carrier.

Claim 26 (Currently amended) A pharmaceutical composition for treating a gastrointestinal disease caused by *Helicobacter pylori* in mammals, comprising the inhibitor according to Claim 22, [and] an inhibitor of gastric acid secretion and a pharmaceutically acceptable carrier.

Claim 27 (Currently amended) A process for preparing a glycoprotein which specifically binds to urease of *Helicobacter pylori*, comprising contacting a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs with *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.

Claim 29 (Currently amended) A process for preparing a glycoprotein as an inhibitor of *Helicobacter pylori* colonization, comprising contacting a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs with *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.

Claim 32 (Currently amended) The inhibitor composition according to Claim [22] 31, wherein the urease immobilized on the column is [recombinant urease] recombinantly produced.

Ŭ

Application/Control Number: 09/833,637

Art Unit: 1653

Claim 35 (Currently amended). A method for inhibiting *Helicobacter pylori* colonization in mammals [including humans], comprising orally administering to [a] <u>said</u> mammal a glycoprotein which specifically binds to urease of *Helicobacter pylori* in an effective amount for inhibiting *Helicobacter pylori* colonization, <u>wherein</u> the glycoprotein [being] <u>is</u> obtained by [isolation and purification from] <u>contacting</u> a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs [using a method which utilizes specific adsorption to *Helicobacter pylori*] <u>with</u> *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.

Claim 36 (Currently amended). A method for inhibiting Helicobacter pylori colonization in mammals [including humans], comprising orally administering to [a] said mammal a glycoprotein which specifically binds to urease of Helicobacter pylori and an inhibitor of gastric acid secretion in an effective amount for inhibiting Helicobacter pylori colonization, wherein the glycoprotein [being] is obtained by [isolation and purification from] contacting a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs [using a method which utilizes specific adsorption to Helicobacter pylori urease] with Helicobacter pylori urease and isolating and purifying the glycoprotein specifically bound to the urease.

Claim 37 (Currently amended) A method for treating a gastrointestinal disease caused by *Helicobacter pylori* in mammals [including humans], comprising orally administering to [a] <u>said</u> mammal a glycoprotein which specifically binds to urease of *Helicobacter pylori* in an effective amount for treating the disease [so as to inhibit] <u>by inhibiting Helicobacter pylori</u> colonization, <u>wherein</u> the glycoprotein [being] <u>is</u> obtained by [isolation and purification from] <u>contacting</u> a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs [using a method which utilizes specific adsorption to *Helicobacter pylori* urease] <u>with *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.</u>

ن

Page 5

Application/Control Number: 09/833,637

Ũ

Art Unit: 1653

Claim 38 (Currently amended) A method for treating a gastrointestinal disease caused by *Helicobacter pylori* in mammals [including humans], comprising orally administering to [a] <u>said</u> mammal a glycoprotein which specifically binds to urease of *Helicobacter pylori* [in] <u>and</u> an inhibitor of gastric acid secretion in an effective amount for treating the disease [so as to inhibit] <u>by inhibiting *Helicobacter pylori* colonization, <u>wherein</u> the glycoprotein [being] <u>is</u> obtained by [isolation and purification from] <u>contacting</u> a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs [using a method which utilizes specific adsorption to *Helicobacter pylori* urease] <u>with *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.</u></u>